fr
Article scientifique
Revue de la littérature
Accès libre
Anglais

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Publié dansEuropean journal of nuclear medicine and molecular imaging, vol. 48, no. 7, p. 2121-2139
Date de publication2021-07
Date de mise en ligne2021-03-05
Résumé

Purpose: In the last decade, the research community has focused on defining reliable biomarkers for the early detection of Alzheimer's disease (AD) pathology. In 2017, the Geneva AD Biomarker Roadmap Initiative adapted a framework for the systematic validation of oncological biomarkers to cerebrospinal fluid (CSF) AD biomarkers-encompassing the 42 amino-acid isoform of amyloid-β (Aβ42), phosphorylated-tau (P-tau), and Total-tau (T-tau)-with the aim to accelerate their development and clinical implementation. The aim of this work is to update the current validation status of CSF AD biomarkers based on the Biomarker Roadmap methodology. Methods: A panel of experts in AD biomarkers convened in November 2019 at a 2-day workshop in Geneva. The level of maturity (fully achieved, partly achieved, preliminary evidence, not achieved, unsuccessful) of CSF AD biomarkers was assessed based on the Biomarker Roadmap methodology before the meeting and presented and discussed during the workshop. Results: By comparison to the previous 2017 Geneva Roadmap meeting, the primary advances in CSF AD biomarkers have been in the area of a unified protocol for CSF sampling, handling and storage, the introduction of certified reference methods and materials for Aβ42, and the introduction of fully automated assays. Additional advances have occurred in the form of defining thresholds for biomarker positivity and assessing the impact of covariates on their discriminatory ability. Conclusions: Though much has been achieved for phases one through three, much work remains in phases four (real world performance) and five (assessment of impact/cost). To a large degree, this will depend on the availability of disease-modifying treatments for AD, given these will make accurate and generally available diagnostic tools key to initiate therapy.

eng
Mots-clés
  • Alzheimer’s disease
  • Aβ42
  • CSF
  • P-tau
  • T-tau
  • Strategic roadmap
  • Alzheimer Disease / diagnosis
  • Amyloid beta-Peptides
  • Biomarkers
  • Humans
  • Peptide Fragments
  • Tau Proteins
Citation (format ISO)
LEUZY, A et al. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. In: European journal of nuclear medicine and molecular imaging, 2021, vol. 48, n° 7, p. 2121–2139. doi: 10.1007/s00259-021-05258-7
Fichiers principaux (1)
Article (Published version)
Fichiers secondaires (1)
Identifiants
ISSN du journal1619-7070
127vues
51téléchargements

Informations techniques

Création20/01/2022 07:56:00
Première validation20/01/2022 07:56:00
Heure de mise à jour16/03/2023 06:33:17
Changement de statut16/03/2023 06:33:14
Dernière indexation12/02/2024 12:22:48
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack